Athos Therapeutics Inc., Los Angeles, CA USA
Co-founder, President & CEO
A pharma company developing precision therapeutics for patients with chronic inflammatory and autoimmune diseases using artificial intelligence and machine learning algorithms (www.athostx.com)

Dyania Health, Los Angeles, CA USA
Co-founder, Chief Scientific Officer
A digital health company that pools anonymized patient health record data into an artificial intelligence-powered system that expedites the availability of clinical trials for cutting edge healthcare to patients who need it most, including covid-19 (www.dyaniahealth.com)

Attica Sciences Ltd., Athens, Greece
Co-founder & Chairman
A pharma company developing innovative preventive and therapeutic small molecule compounds derived from olive oil and mastic gum (https://atticasciences.com).

Center for Systems Biomedicine at UCLA, Los Angeles, CA USA        2012 – 2018
Founder/Director

  • Leading 5 technology platforms, 2 research programs and 1 educational program
  • Developed one of the largest drug discovery units in any academic institute in the USA
  • Manages a multidisciplinary team of experts in the fields of medicine, biology, computer science and engineering
  • Directing all aspects of fundraising, marketing, public relations, staffing and budget   management 

UCLA School of Medicine, Los Angeles, CA USA                                  2012 – 2018
Associate Professor of Medicine

  • Supervising a team of 8 (junior faculty, post-doctoral fellows, Ph.D students and lab technicians).
  • Elected member of the UCLA Institute for Molecular Medicine (IMED), the UCLA Jonsson Comprehensive Cancer Center (JCCC), the MCIP Ph.D program and the Broad Stem Cell Center at UCLA. 

Biotechnology Finance & Strategy Consultant, Los Angeles, CA USA             2015 – present

  • Developed a strategy for investors to identify promising drugs in their developmental phase and assess the key factors that affect the success of the clinical trials and the value of the drug products
  • Created a novel financial model for drugs in the market, close to be launched in the market and in developmental stage
  • Knowledge of comparing DCF, binomial lattice, Black-Scholes, VC and the Schwartz-Moon financial models for pharma/biotech drugs
  • Performed research analysis in collaboration with major investment banks and identified current methodologies and future needs of investment banks to perform valuation analysis of biotechnology products and companies

Previous positions

2010-2012
Assistant Professor of Immunobiology
Department of Cancer Immunology & AIDS
Dana-Farber Cancer Institute
Boston, MA USA

2010-2012
Assistant Professor (Tenure-track)
Department of Microbiology & Immunobiology
Harvard Medical School
Boston, MA USA

2007-2009
Post-doctoral Fellow
Kevin Struhl laboratory
Department of Biological Chemistry & Molecular Pharmacology
Harvard Medical School
Boston, MA USA